Syntekabio will showcase its AI drug discovery platforms, DeepMatcher® and NEO-ARS™, at the US-Korea Conference 2022 on August 19 in Arlington, Virginia. Dr. Kilyoung Kim, the company’s CSO, will present these innovative technologies, emphasizing their significance in enhancing drug discovery. The conference aims to promote collaboration between American and Korean professionals in science, technology, and entrepreneurship.
Syntekabio, a leader in AI-driven drug discovery and development, is poised to unveil its advanced cloud platforms, DeepMatcher® and NEO-ARS™, at the forthcoming US-Korea Conference (UKC) 2022. Scheduled for August 19, this event will be held in Arlington, Virginia, allowing participants to explore innovations in science and technology. The conference supports collaboration between U.S. and Korean professionals in various fields, fostering connections among emerging entrepreneurs and established business figures.
The 4th Innovation and Entrepreneurship Symposium (IES) will serve as a key platform for Syntekabio to demonstrate its pivotal technologies for AI drug discovery. Dr. Kilyoung Kim, Chief Scientific Officer and president of Syntekabio USA, will present insights on the company’s recent advancements and the opportunities provided by these innovative platforms. This launch signifies a major step in enhancing drug discovery efficiency, benefiting global health initiatives.
Participants will have the opportunity to engage with Syntekabio’s leadership after the presentation, offering valuable media interaction. Syntekabio’s technologies aim to deliver transformative medicine while adhering to international standards, exemplifying their commitment to improving health outcomes across the globe. For detailed information regarding the symposium and to learn more about Syntekabio’s offerings, interested parties may visit the respective websites.
The upcoming US-Korea Conference (UKC) serves as a critical venue for dialogue and networking among professionals from diverse sectors, particularly focusing on recent advancements in science, engineering, and technology. This year’s symposium will emphasize collaboration between the U.S. and South Korea, showcasing innovative solutions in medicine and fostering entrepreneurship. Syntekabio’s participation underlines the growing importance of artificial intelligence in drug development, marking a new era in the pharmaceutical industry where advanced technologies can substantially accelerate research and bring forth novel treatments for various diseases.
In summary, Syntekabio’s presentation of its AI-based drug discovery platforms, DeepMatcher® and NEO-ARS™, at the 2022 US-Korea Conference epitomizes the synergy between innovative technology and health advancements. This event not only highlights Syntekabio’s pivotal role in the biotech sector but also reinforces the importance of U.S.-Korean collaborations in fostering breakthroughs in medicine. As the organization continues to push boundaries in drug development, the implications for global health and innovation are profound and far-reaching.
Original Source: www.globenewswire.com
